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Recombinant avipox viruses are being widely evaluated as vaccines. To address how these viruses, which
replicate poorly in mammalian cells, might be immunogenic, we studied how canarypox virus (ALVAC)
interacts with primate antigen-presenting dendritic cells (DCs). When human and rhesus macaque monocyte-
derived DCs were exposed to recombinant ALVAC, immature DCs were most susceptible to infection. However,
many of the infected cells underwent apoptotic cell death, and dying infected cells were engulfed by uninfected
DCs. Furthermore, a subset of DCs matured in the ALVAC-exposed DC cultures. DC maturation coincided
with tumor necrosis factor alpha (TNF-a) secretion and was significantly blocked in the presence of anti-
TNF-a antibodies. Interestingly, inhibition of apoptosis with a caspase 3 inhibitor also reduced some of the
maturation induced by exposure to ALVAC. This indicates that both TNF-a and the presence of primarily
apoptotic cells contributed to DC maturation. Therefore, infection of immature primate DCs with ALVAC
results in apoptotic death of infected cells, which can be internalized by noninfected DCs driving DC matu-
ration in the presence of the TNF-a secreted concomitantly by exposed cells. This suggests an important
mechanism that may influence the immunogenicity of avipox virus vectors.
Recombinant avipox viruses, such as canarypox virus
(ALVAC) or fowlpox virus, are of special interest in the field
of vaccine development (reviewed in reference 38). These vec-
tors are safe, since their replication is restricted to avian hosts.
Even in immunocompromised mammalian hosts, systemic
spread does not occur (57). In addition, they are large enough
to be efficiently loaded with genes of different infectious or
tumor agents. Finally, they can elicit immune responses in
people previously exposed to vaccinia virus circumventing po-
tential anti-vector immune responses in vaccinia virus-immune
persons (10). Thus, avipox viruses provide a potentially useful
vehicle to safely induce immune responses against a variety of
antigens.
Since ALVAC has been shown to be more efficacious than a
fowlpox virus-based vector, providing a comparable protective
effect to that of a thymidine kinase-disrupted replication-com-
petent vaccinia virus vector (58), many studies using different
ALVAC constructs have been performed. ALVAC constructs
encoding foreign proteins have been shown to induce humoral
and cellular immune responses against a variety of infectious
pathogens. These include rabies virus (19, 58), feline immuno-
deficiency virus (59), human immunodeficiency virus type
(HIV-1) and HIV-2 (1, 4, 6, 15, 18, 35, 49), Japanese enceph-
alitis virus (32, 43), rabbit hemorrhagic disease virus (17), and
canine distemper virus (CDV) (39, 55), as well as tumor anti-
gens (25, 34, 46). In fact, very recent studies revealed that
mucosal application of ALVAC containing CDV genes in-
duced high titers of neutralizing antibodies (Abs) and protec-
tion against a mucosal challenge with CDV (63). To potentially
optimize the vaccine efficiency of ALVAC, we were particu-
larly interested in how the virus imparts immunity in mamma-
lian hosts without extensive replication, tissue damage, and
subsequent spread of infection between cells.
Dendritic cells (DCs) are potent antigen-presenting cells
central to immune activation and exist in an immature state at
body surfaces and mucosal sites. Immature DCs can capture
antigens such as extracellular and facultative intracellular bac-
teria, parasites, and dying cells (reviewed in references 5 and
54). This is followed by migration to the draining lymph nodes,
where as mature DCs they present the antigen to lymphocytes.
Furthermore, DCs express a variety of surface molecules nec-
essary for the entry of viruses, such as CD4, chemokine recep-
tors, for HIV and simian immunodeficiency virus (SIV), CD46
for measles virus (5), and DC-SIGN for the binding of HIV
(22). Therefore, they can directly be infected by these and
other viruses.
Since direct targeting of DCs with ALVAC might enhance
immune responses against ALVAC-encoded antigens, we in-
vestigated the consequences of the interaction of ALVAC with
DCs. While both immature and mature DCs were infected
with ALVAC, immature DCs were more sensitive to infection.
Many ALVAC-infected immature DCs rapidly underwent apo-
ptotic cell death, and endocytosis of infected, dead or dying
DCs by uninfected immature DCs was observed. Concurrently,
a subpopulation of ALVAC-exposed DCs matured. Matura-
tion was largely driven by the tumor necrosis factor alpha
(TNF-a) secreted following exposure to ALVAC and partially
by the ingestion of infected cell debris. These data suggest a
mechanism for ALVAC-induced DC maturation, which in-
volves apoptosis and TNF-a secretion, and this mechanism
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may augment the presentation of virus-encoded antigens and
thereby have a significant impact on the efficiency of these
viruses in vaccine development.
MATERIALS AND METHODS
Viral constructs. All ALVAC constructs used in this study were engineered at
Virogenetics, Troy, N.Y. Constructs include the strain vCP172, containing the
sequence for the SIV gag (encoding for the SIV core protein p27) and pol
(encoding for the viral reverse transcriptase and integrase), vCP180, which con-
tains in addition to SIV gag-pol the gene for the viral envelope (env), vCP205
(HIV gag, protease, and env) and the parental strain (ALVAC). Heat-inactivated
virus was obtained by incubating virus at 56°C for 30 min. Successful inactivation
was confirmed by a lack of protein expression by DCs exposed to the heat-
inactivated virus (data not shown). ALVAC was UV inactivated in 1 mM Tris in
a 35-mm dish for 10 min with constant stirring. Inactivation was confirmed by
performing a standard virus titration plaque assay.
Culture medium. RPMI 1640 (Cellgro; Fisher Scientific, Springfield, N.J., or
BioWhittaker, Walkersville, Md.), supplemented with 2 mM L-glutamine
(GIBCO-BRL/Life Technologies [GIBCO-BRL], Grand Island, N.Y.), 50 mM
2-mercaptoethanol (Sigma Chemical Company, St. Louis, Mo.), 10 mM HEPES
(GIBCO-BRL), penicillin (100 U/ml)-streptomycin (100 mg/ml) (GIBCO-BRL),
and 1% human plasma (heparinized) or 10% heat-inactivated fetal calf serum
(PAA Laboratories, Parker Ford, Pa.) screened negative for virus, mycoplasma,
and below the detection limits for endotoxin.
Generation of human and macaque DCs. Heparinized human blood was
obtained from healthy donors or as leukopaks from the New York City Blood
Bank or RH Labs, Baltimore, Md. Peripheral blood mononuclear cells (PBMCs)
were isolated by centrifugation on Ficoll-Hypaque (Amersham Pharmacia Bio-
tech AB, Uppsala, Sweden). T cells were removed by adhering 8 3 106 cells/well
in a six-well tray (Falcon, Lincoln Park, N.Y.) for 1 to 2 h at 37°C. Nonadherent
T cells were carefully washed away, and adherent monocytes were cultured for 6
to 7 days in 3 ml of medium containing 100 U of interleukin-4 (IL-4; R&D
Systems, Minneapolis, Minn.) per ml and 1,000 U of granulocyte-macrophage
colony-stimulating factor (GM-CSF) (Immunex, Seattle, Wash.). In some exper-
iments, immature human DCs were generated from a highly enriched population
of CD141 cells obtained by the magnetic bead selection of monocytes (Miltenyi
Biotec, Auburn, Calif.). The cells were placed into tissue culture flasks or six-well
plates at 106 cells/ml and cultured for 6 to 7 days in the presence of 100 to 1,000
U of IL-4 and 1,000 U of GM-CSF per ml.
Heparinized rhesus macaque (Macaca mulatta) blood was obtained from adult
animals. All animals tested negative for Abs to SIV, type D retroviruses, and
simian T-lymphotropic virus type 1, and were housed at the Tulane Regional
Primate Research Center or the animal facilities at the Walter Reed Army
Institute for Research. Animal care operations were in compliance with the
regulations detailed under the animal welfare act, and in the Guide for the Care
and Use of Laboratory Animals. PBMCs were separated by centrifugation on
Ficoll-Hypaque. A total of 12 3 106 to 15 3 106 PBMCs were plated per well of
a six-well tray and incubated for 1 to 2 h at 37°C. After careful removal of
nonadherent cells (by washing with warm phosphate-buffered saline [PBS]), the
adherent monocytes were cultured for 6 to 7 days in the presence of 100 U of
IL-4 and 1,000 U of GM-CSF per ml. In some experiments, CD141 monocytes
were selected using the magnetic activated cell sorting (MACS) system (Miltenyi
Biotec), plated at 106 cells/ml in six-well plates, and cultured in the presence of
GM-CSF and IL-4 (see above).
For both human and monkey DCs, additional cytokines were added on days 2,
4, and 6. Immature DCs were obtained after the 6 to 7 days in culture with
GM-CSF and IL-4. To generate mature DCs, 50% of the medium was substi-
tuted with monocyte-conditioned medium (MCM) on day 6 or 7, and the cells
cultured for an additional 2 days. When immature and mature DCs were directly
compared, immature DCs were cultured for the additional 2 days in the absence
of MCM. MCM was generated using a slightly modified protocol from that
previously described (45). Briefly, bacteriologic dishes (Falcon) were coated with
4 ml of a 100-mg/ml concentration of human gamma globulin (Bayer Corp.,
Elkhart, Ind.) in PBS and incubated for 10 min at room temperature before
being washed four times with PBS. Then, 9 3 107 human PBMCs were plated in
each dish and incubated for 1 h at 37°C. Nonadherent cells were removed, 8 ml
of fresh medium was added, and the dishes were incubated for 24 h at 37°C. The
24-h cell-free supernatants were pooled, filtered, and frozen at 220°C before
use.
The phenotype of the DCs was routinely monitored by two-color fluorescence-
activated cell sorter (FACS) analysis on a FACScan flow cytometer (Becton
Dickinson, Mountainview, Calif.). Fluorescein isothiocyanate (FITC)-conju-
gated monoclonal Abs (MAbs) against human major histocompatibility complex
(MHC) class II (anti-HLA-DR-FITC) (Becton Dickinson Immunocytometry
Systems [BDIS], San Jose, Calif.) were used in combination with phycoerythrin
(PE)-conjugated MAbs against human CD25 (BDIS), CD80 (BDIS), CD83
(Coulter Corp., Miami, Fla.), and CD86 (PharMingen, San Diego, Calif.). Im-
mature DCs typically were HLA-DR11, CD8611, CD801/low, CD832/weak, and
CD252, while mature DCs expressed HLA-DR111, CD86111, CD2511,
CD8011, and CD8311.
Infection of DCs with ALVAC. DCs were counted and cultured at 105 large
cells/well in 96-well round-bottom trays (Linbro). Either the original culture
medium in which the DCs were generated (original medium) was reused without
the addition of fresh cytokines or else fresh medium was prepared that contained
100 U of IL-4 and 1,000 U of GM-CSF per ml. DCs were infected with the
indicated ALVAC construct at a multiplicity of infection (MOI) of 5 to 10.
Where indicated, the cells were washed twice after 1 h at 37°C before being
cultured for up to 4 days. When mature and immature DCs were compared, both
DC preparations were resuspended in original medium. The DC phenotype was
monitored by FACS analysis prior to and at various times after exposure to
ALVAC. Uninfected control DCs were included and analyzed for comparison.
Alternatively, 2 3 106 to 5 3 106 immature human DCs were resuspended in
0.1 ml of culture medium in 15-ml conical tubes and incubated with vCP205
(MOI of 0.2 to 10) for 2 h at 37°C. Cells were washed and placed at 106 cells/ml
in a 24-well plate (Costar; Corning, Inc., Corning, N.Y.). After 24 h, cell super-
natants were collected and stored at 270°C for subsequent cytokine analysis. At
the same time, DCs were harvested and counted and the viability was monitored
by trypan blue staining.
In some experiments, ALVAC-infected or uninfected immature DCs (1 3 105
to 2 3 105) were placed into the wells of a 96-well culture tray (Millipore
Multiscreen Filtration System, MAMCS9610). The upper filtration plate (Milli-
pore MACMS4510) was positioned onto the culture tray, and uninfected DCs in
cytokine-containing medium were then placed at various concentrations into the
upper wells. The plates were cultured for up to 4 days at 37°C, and the DCs were
collected from the upper (uninfected cells) and lower (infected versus uninfected
cells) chambers at specific time points for FACS analysis.
Identification of ALVAC infection. In order to identify recombinant ALVAC-
infected cells, cells were stained intracellularly using a polyclonal rabbit anti-
canarypox virus serum (Virogenetics) at a 1:10,000 dilution. Cells were washed
twice and fixed in 4% paraformaldehyde-PBS (wt/vol) for 10 min at 4°C. After
two washes, cells were incubated in 1% saponin (Sigma) for 30 min at 4°C,
washed twice with PBS, and resuspended in 100 ml of 0.1% saponin containing
the diluted rabbit serum. After 30 min of incubation at 4°C, the cells were washed
twice with 0.1% saponin, resuspended in 100 ml of 0.1% saponin containing an
FITC-conjugated donkey anti-rabbit immunoglobulin (Jackson ImmunoRe-
search Laboratories, West Grove, Pa.) at a 1:200 dilution, and incubated for 30
min at 4°C. Finally, cells were washed twice and monitored by FACS. Back-
ground staining was monitored on uninfected cells from the same donor and on
cells incubated with normal rabbit immunoglobulin.
To detect expression of SIV proteins in infected cells, the viral constructs
vCP172 (SIV gag and pol) or vCP180 (SIV gag, pol, and env) were used. Using the
anti-SIV p27 MAb 55-2F12 (NIH AIDS Research and Reference Reagent Pro-
gram), infection was monitored either by immunoperoxidase staining on cytospin
preparations as described previously (26) or by intracellular FACS staining (see
above). Here, biotinylated anti-SIV p27 MAb was used at a 1:400 dilution, and
Fluorescein (DTAF)-conjugated streptavidin (Jackson ImmunoResearch) was
used at 1:200.
To detect HIV p24, infected DCs were fixed and permeabilized using a 2%
formaldehyde–0.1% saponin buffer. After a 20-min incubation, the cells were
washed in ice-cold PBS–0.1% saponin. The cells were then incubated with a
murine anti-p24 MAb (Dako, Carpinteria, Calif.) or the isotype control (South-
ern Biotechnology Associates, Birmingham, Ala.) at a 1:10 dilution followed by
a PE-conjugated goat anti-mouse immunoglobulin (Southern Biotechnology As-
sociates) at 1:200.
Apoptosis assays. Apoptotic cells were identified using the TUNEL (terminal
deoxynucleotidyltransferase-mediated dUTP nick end labeling) technique, and
assays were performed according to the manufacturer’s guidelines (Boehringer
Mannheim and Roche Molecular Biochemicals, Indianapolis, Ind.). In brief,
cells were harvested at different time points after infection, washed twice with
PBS in a 96-well V-bottomed tray (Linbro), and fixed in 4% paraformaldehyde–
PBS (wt/vol) for 30 min at room temperature. After centrifugation (2,000 rpm
for 2 to 3 min), cells were washed once with 200 ml of PBS, resuspended in 100
ml of permeabilization solution (0.1% Triton X-100 in 0.1 sodium citrate), and
incubated for 2 min at 4°C. The cells were washed twice (2,000 rpm for 2 to 3
min) using cold PBS, resuspended in 50 ml of TUNEL reaction or control
mixture, and incubated for 60 min at 37°C in 5% CO2. Cells were washed twice
in PBS and analyzed by FACS.
Fluorescent labeling of DCs. DCs were stained with the green fluorescent dye,
5-chloromethylfluorescein diacetate (CMFDA), or the red fluorescent dye,
5-(and-6)-{[(4-chloromethyl) benzoyl]amino}tetramethylrhodamine (CMTMR)
(Molecular Probes, Eugene, Oreg.) according to the manufacturers’ instructions.
Cells were placed into a 1.5-ml Eppendorf tube, centrifuged, and resuspended in
100 ml of prewarmed (37°C) probe-containing (5 mM) RPMI. After 15 min at
37°C, the DCs were centrifuged, resuspended in prewarmed medium, and incu-
bated for an additional 30 min at 37°C. The cells were centrifuged once more and
then counted prior to use.
Confocal microscopy. CMTMR (red)-stained infected DCs and CMFDA
(green)-stained, uninfected DCs were cocultured at a ratio of 1:1 for 2 to 3 days.
After culture, the cells were seeded in serum-free RPMI into alcian blue (Sigma)
coated Lab Tek tissue culture chambers (Nunc, Naperville, Ill.) (27) at a mini-
mum number of 104 cells/chamber. The chambers were incubated for 1 h at 37°C,
the medium was aspirated, and the adhered cells were immediately fixed with 4%
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paraformaldehyde–PBS (wt/vol) for 20 min at room temperature. Specimens
were examined by confocal laser scan microscopy (Zeiss) using adequate filter
settings for fluorescein-rhodamine excitation and emission, respectively. Optical
sections were approximately 0.75 mm thick, and images were overlaid using the
microscope software provided by Zeiss.
Inhibition of apoptosis. Apoptosis of infected cells was inhibited using the
Caspase-3/CPP32 inhibitor Z-DEVD-FMK (Kamiya Biomedical Company, Se-
attle, Wash.) (28). Stock solutions (100 mM) of Z-DEVD-FMK in dimethyl
sulfoxide (DMSO) were stored at 4°C. DCs were preincubated with Z-DEVD-
FMK at a concentration of 250 or 500 mM for 30 min at 37°C in 5% CO2 before
infection with recombinant ALVAC. To ensure that the drug did not interfere
with DC maturation per se, a separate aliquot of DCs was pretreated with
Z-DEVD-FMK prior to addition of MCM as the maturation stimulus.
TNF-a assays. Cell supernatants were collected from ALVAC-exposed and
unexposed DC cultures after 1 to 4 days of incubation and stored at 220°C.
TNF-a concentrations were measured using commercially available ELISAs
specific for human (R&D Systems) or monkey (U-Cytech, Utrecht, The Neth-
erlands) TNF-a.
In some experiments, infected DCs were cultured in the presence of 20 mg of
neutralizing anti-human TNF-a Abs (R&D Systems) or control immunoglobulin
G1 (IgG1; PharMingen) per ml. Cell supernatants were collected 1 day after
infection and analyzed for the presence of TNF-a. The DC phenotype was
determined at days 1 and 3 by FACS analysis. Cells cultured for 3 to 4 days had
additional Abs added at day 2 of cultures.
RESULTS
Infection of primate immature and mature DCs by recom-
binant ALVAC. To determine whether DCs could be infected
with ALVAC and to monitor the degree of infection, we chose
the construct vCP172. This enabled us to monitor expression of
both ALVAC and SIV antigens in the exposed DC popula-
tions. Mature and immature DCs were infected with vCP172
(MOI of 10). At multiple time points after infection, cells were
stained intracellularly with either a polyclonal rabbit anti-
ALVAC serum or the anti-SIVp27 MAb. Table 1 demon-
strates the kinetics of infection obtained in a representative
experiment using human DCs. Immature DCs exhibited a
higher frequency of infection compared to mature DCs. A
considerable percentage, but not all infected DCs (ALVAC
positive), also expressed the protein encoded by the SIV gag
gene in the viral construct. In subsequent experiments infec-
tions were mostly monitored at single time points. However,
both human and rhesus macaque immature DCs always ex-
pressed ALVAC-specific proteins to a notably higher percent-
age (about two- to fourfold) than mature DCs, and numbers of
ALVAC-positive cells were higher than those of p27-positive
DCs (when infections using vCP172 or vCP180 were analyzed).
This might simply reflect differences in the sensitivity of the
Abs or that not all vCP172-infected, ALVAC-positive cells
expressed SIV p27. It was unlikely that the ALVAC positivity
reflected virus bound to the cell surface, since cells not per-
meabilized prior to staining were negative (data not shown).
Immature and mature rhesus macaque DCs were also in-
fected by recombinant ALVAC (Fig. 1). While immature DCs
were more susceptible to infection, as seen with human DCs,
the average numbers of infected macaque cells were as much
as twofold lower than those detected in human DCs. Immu-
noperoxidase staining of cytospins for p27 expression identi-
fied SIV p27-positive DCs within infected rhesus macaque and
human DCs.
TABLE 1. Frequency of canarypox virus-infected immature and
mature human DCs
DC
Frequencya at (time postinfection [h]):
6 12 18 24 36 48
Mature 8/0 19/3 33/4 15/3 14/4 11/2
Immature 28/14 42/34 64/41 43/30 48/12 48/8
a Immature or mature DCs were infected with vCP172 (MOI of 10) and
harvested at various time points after infection. Intracellular FACS staining
using a polyclonal rabbit anti-canarypox virus serum and a MAb against SIV p27
was used to detect ALVAC-positive and p27-positive cells. The data are pre-
sented as the percent ALVAC-positive cells/percent p27-positive cells above
background control staining.
FIG. 1. ALVAC infection of immature DCs and subsequent apoptotic cell death. (A and B) Immature DCs were infected with vCP172 (MOI of 10). At 24 h after
infection, p27 expression was monitored by either intracellular FACS staining (A, rhesus macaque) or by immunoperoxidase staining (dark reaction product) on
cytospins (B; magnification, 31,000). The log fluorescent intensity of FITC (Log FITC) is shown on the y axes, and the forward light scatter (FSC) is shown on the
x axes. The percentages of SIV-p27-positive cells (arrowhead), above IgG control, are shown in panel A. These data are representative of more than five experiments.
(C) vCP172-infected versus uninfected (Medium) immature human DCs were analyzed for the presence of apoptotic cells using a TUNEL FACS assay at the indicated
times of culture. The percent TUNEL-positive cells at each time point of one representative experiment of three are shown.
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When vCP172-infected immature DCs were cultured for 3 to
4 days, considerable cell death was observed. On average,
uninfected cultures yielded approximately twice the numbers
of viable cells on day 4 compared to infected cultures. This was
further supported by the reduced forward scatter (size) and
increased side scatter (granularity) of infected DCs that was
evident upon FACS analysis. To investigate the mechanism of
cell death, infected and uninfected DCs were harvested at
multiple time points and FACS analysis was performed to
detect apoptotic, TUNEL-positive cells. Figure 1C shows the
kinetics of the appearance of TUNEL-positive cells after in-
fection with ALVAC. These studies demonstrate a rapid in-
crease in the numbers of apoptotic cells shortly after infection
of immature DCs with recombinant ALVAC.
Infected DCs are phagocytosed by uninfected DCs. DCs
have been shown to take up dead or dying cells (2, 3). There-
fore, we examined whether the cell fragments from infected
dying ALVAC-infected cells could be phagocytosed by unin-
fected DCs. CMFDA (green)-stained, uninfected DCs were
cultured with CMTMR (red)-stained infected DCs for 3 days.
FACS analysis of the cocultures revealed a significant propor-
tion of green-red double-positive cells, as well as single green
large cells in contrast to control cultures of uninfected red and
uninfected green DC mixtures (data not shown). Confocal
microscopic analysis of FACS-sorted double-positive or single-
positive green fractions revealed that the double-positive frac-
tion comprised mainly green (uninfected) cells with large red
inclusions (Fig. 2, lower panels). While also many single-pos-
itive green cells contained red inclusions (Fig. 2, upper panels),
they were considerably smaller than those detected in the dou-
ble-positive fraction. Internalization of green, uninfected cells
by red, infected DCs was not observed. Therefore, these results
suggest that infected cells dying by apoptosis (Fig. 1C) were
phagocytosed by uninfected DCs.
DC maturation following ALVAC infection. When cultures
of ALVAC-infected immature DCs were observed more
closely a second phenomenon was appreciated. Coincident
with the cell death induced by exposure to ALVAC (Fig. 1C),
there was a modulation of the DC phenotype (Fig. 3). Com-
pared to the uninfected controls, increased expression of
CD25, CD80, CD83, and CD86 was readily detected in at least
a subset of cells after 3 to 4 days. In both human and monkey,
the percentage of canarypox virus-exposed DCs expressing
CD25 varied between donors and ranged between 5 and 35%.
Uninfected control DCs sometimes contained a subset of spon-
taneously matured DCs, but this was always considerably
smaller than that observed in ALVAC-infected cultures.
More detailed examination of infected human and rhesus
macaque immature DCs revealed that maturation could be
detected within 1 day of exposure to the virus (Fig. 3B; see also
Fig. 8B). Figure 3B illustrates the phenotypic changes detected
in a rhesus macaque DC preparation pulsed with vCP172 1 to
3 days earlier. As early as 1 day postexposure, the levels of
CD25, CD80, CD83, and CD86 had increased, and this was
still evident at day 3. Although maturation began by day 1 after
infection, the expression of maturation markers, particularly
CD25, often increased over the next 2 to 3 days.
To verify that it was the canarypox virus and not the foreign
introduced genes driving maturation, immature DCs were in-
fected with vCP180 (containing SIV gag, pol, and env) or with
the parental strain not containing SIV-genes (ALVAC). Fig-
ure 4A shows that in both cultures a similar subset of DCs
demonstrated increased CD25 expression (21 and 19%, re-
spectively). In numerous experiments, different ALVAC con-
structs containing or lacking various viral genes were used, and
maturation was observed with all constructs (data not shown).
Hence, canarypox virus itself mediates induction of DC mat-
uration and not by foreign genes (or the proteins encoded by
those genes) that have been engineered into the vectors.
In an attempt to further characterize the maturing subset
within ALVAC-exposed DC cultures, CD25-positive mature
DCs were separated from CD25-negative immature DCs by
cell sorting 3 to 4 days after infection with vCP180. Each subset
was then analyzed for the expression of SIV p27 by intracel-
lular FACS staining. Considerably fewer p27-positive cells
were detected in the CD25-positive fraction compared to
FIG. 2. Phagocytosis of ALVAC-infected cells by immature, uninfected DCs. Green-stained, uninfected DCs were cocultured with red-stained, infected DCs. After
3 days, cells were sorted into single-positive green cells (top) or double-positive red-green cells (bottom). The cell populations were further analyzed using confocal
laser scan microscopy. Demonstrated are images yielded with filter settings for fluorescein only (left), rhodamine only (middle), and with both images overlaid (right)
(magnification, 31,000).
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CD25-negative cells (Fig. 4B). Hence, viral infection or gene
expression itself did not seem to be directly responsible for
maturing the DCs. However, this phenomenon was dependent
on viable virus. Heat inactivation of virus abrogated its ability
to induce both cell death and maturation (Fig. 4C). To exclude
the possibility that heat treatment inactivated a temperature-
sensitive component of the virus stock that was inducing cell
death and/or the maturation effect, UV-inactivated virus was
also applied to DCs. As with heat-inactivated virus, UV-inac-
tivated ALVAC did not induce DC maturation (data not
shown).
Inhibition of apoptosis partially interferes with maturation.
To investigate whether the induction of apoptotic cell death
was a prerequisite for DC maturation, DCs were treated with
the caspase-3 inhibitor Z-DEVD-FMK. Caspase-3 is believed
to be involved in all pathways of apoptotic cell death (37).
Immature DCs were pretreated with 250 or 500 mM Z-DEVD-
FMK for 30 min. ALVAC was then added to the wells, and
cultures were analyzed 4 days later for CD25 expression as a
marker for mature DCs. Figure 5 shows that significantly less
CD25 expression was detected in the presence of Z-DEVD-
FMK (but not the diluent control). The addition of Z-DEVD-
FMK to MCM-treated immature DCs did not interfere with
MCM-induced maturation (data not shown). Z-DEVD-FMK
did not modify the expression of ALVAC-specific proteins in
exposed cultures as determined by intracellular FACS staining
(data not shown). When apoptosis was monitored in ALVAC-
exposed cultures in the presence of Z-DEVD-FMK, the per-
centage of TUNEL-positive cells was reduced by approximately
70% (data not shown), while higher drug concentrations re-
peatedly lead to drug-induced cell death. Thus, blocking apo-
ptotic cell death in the ALVAC-infected cultures reduced the
amount of DC maturation, indicating that the presence of
primarily apoptotic cells rather than a minor population of
primarily necrotic DCs drove DC maturation, at least partially.
TNF-a secreted by ALVAC-exposed DCs facilitates DC mat-
uration. The previous findings suggested that apoptosis con-
tributed to maturation. However, even high doses of a
caspase-3 inhibitor did not completely reverse the maturation
effect of ALVAC infection (Fig. 5). The evidence that a soluble
factor released by ALVAC-pulsed DCs might contribute to the
maturation of healthy DCs was initially obtained using two
different strategies. First, immature DCs were infected with
ALVAC, free virus was washed off, and the infected cells were
added to uninfected, immature DCs, which had been previ-
ously stained green using CMFDA. After 4 days, DC cultures
were monitored for maturation (CD25-PE staining) in the
infected (CMFDA-negative) and uninfected (CMFDA-posi-
tive) populations. Figure 6, upper right, shows that similar
maturation (CD25 expression) was detected in both infected
(CMFDA-negative) and uninfected (CMFDA-positive) DCs.
The addition of supernatant, middle panel, from infected cells
harvested directly after washing out the virus did not change
the phenotype of uninfected cells. Thus, the maturation effect
was dependent on the presence of infected cells, and residual
cell-free virus could be excluded as a mediator.
A second approach also suggested that soluble products
produced by ALVAC-exposed DCs were able to promote DC
maturation. Immature DCs cultured on the other side of a
porous membrane were induced to mature only when ALVAC-
infected DCs were present in the opposing chamber (data not
shown). Hence, the infected population released a factor(s)
that was able to induce maturation of the uninfected DCs.
TNF-a is secreted in response to viral infections (44), as well
as being able to induce DC maturation in vitro (5). Conse-
quently, the presence of TNF-a in the ALVAC-infected DC
cultures was investigated. Cell supernatants were collected
from infected and uninfected DC cultures 1 to 3 days following
exposure to ALVAC. Significant TNF-a production occurred
within 1 day of exposure of immature human DCs to canarypox
virus and was dependent on the infectious dose used to infect
the DCs but was not influenced by the presence (or absence) of
the foreign genes in the construct (Fig. 7A and B). Similar
TNF-a secretion was detected in vCP172-infected rhesus ma-
caque DCs (Fig. 7C). Interestingly, inclusion of neutralizing
anti-human TNF-a Abs in the infected human DC cultures
resulted in diminished TNF-a detection and prevented much
of the DC maturation measured by CD83 expression within a
day of infection (Fig. 8). Partial block of DC maturation was
also observed at day 3 (data not shown). Therefore, TNF-a
secreted by immature DCs in response to infection with
ALVAC contributed significantly to maturation of uninfected
DCs.
DISCUSSION
In recent years there has been an immense increase in the
number of publications investigating the interaction of DCs
FIG. 3. Maturation of DCs in vCP172-infected cultures. (A) Immature hu-
man DCs were infected with vCP172 (MOI of 10). Infected (1) and uninfected
(2) DCs were cultured for 4 days. After culture, the cells were harvested and
monitored for the expression of CD25-, CD83-, and CD86-PE (log PE y axes)
versus HLA-DR–FITC (x axes). The percentage of large cells expressing CD25
and CD83 above the isotype control are indicated. (B) Immature rhesus ma-
caque DCs were infected with vCP172 (1) (MOI of 10) or not (2) and cultured
for 1 to 3 days before being harvested and analyzed. FACS analysis was per-
formed on cells stained with FITC–anti-HLA-DR versus PE-immunoglobulin,
-anti-CD25, -CD80, -CD83, or -CD86. Similar data were obtained from more
than five experiments with human DCs and three different monkey donors.
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with various viruses. These encompass measles virus (20, 29,
30, 51, 52, 60), vaccinia virus (14, 16), herpes simplex virus (47),
polyomavirus (13), and most extensively the immunodeficiency
viruses HIV and SIV (7, 9, 23, 26, 31, 41, 42, 62, 65). While
DCs may play a role in the pathogenesis of these infections,
they are also likely to be critical in activating virus-specific
immune responses. Recombinant avipox virus constructs have
proven to be both immunogenic and safe in humans (6, 15, 19,
32, 34, 49) and are, therefore, of great interest in vaccine
research. One study was published on the use of recombinant
fowlpox virus for the transfer of genes to DCs (8). However,
little detail has been placed on understanding the interactions
between DCs and potential viral vectors, nor on what influence
such infections could impart on normal DC function. In the
present study, we investigated the impact of direct in vitro
infection of ex vivo generated DCs with ALVAC in order to
determine how to possibly enhance their immunogenicity for
applications in future vaccine development.
Our studies confirmed that significant numbers of immature
FIG. 4. Induction of maturation is stimulated by viable canarypox virus. (A) Immature human DCs were infected with an MOI of 10 of either vCP180 or the parental
strain (ALVAC) or left uninfected (medium). CD25 surface expression by large HLA-DR-positive cells was assessed 4 days after infection (CD25-PE, y axes;
HLA-DR–FITC, x axes). The percentage of CD25-positive cells (above isotype control) are indicated in each panel (highlighted by arrowheads). (B) Immature human
DCs that had been infected with vCP180 3 to 4 days earlier were sorted into CD25-negative (CD25 neg.) and CD25-positive (CD25 pos.) fractions. Each fraction was
then immunostained for intracellular expression of p27 and analyzed by FACS. The percentage of SIV p27-positive cells, above the immunoglobulin control, is shown
for each subset. (C) Immature DCs (human) were infected with live (ALVAC) or heat-inactivated (H.I.) ALVAC or left untreated (medium). After 4 days the DCs
were examined for CD25 expression by FACS. The percentages of CD25-positive large cells (compared to the isotype control) are shown in each panel. The
CD25-positive subset is highlighted by an arrowhead.
FIG. 5. Inhibition of maturation of ALVAC-infected DCs by the addition of
a caspase 3 inhibitor. A total of 250 or 500 mM Z-DEVD-FMK, or the equivalent
dilution of DMSO diluent for the high dose (DMSO), were added to immature
DCs 30 min before infection with ALVAC. Inhibition of maturation was assessed
by the lack of CD25 expression 4 days after infection using the DMSO-treated
cells as the 100% matured population. The data represent the mean percentages
of CD25-expression (% CD25 pos.) of three experiments.
FIG. 6. Maturation of uninfected DCs by ALVAC-infected immature DCs.
Immature DCs were infected with ALVAC, and free virus was washed out.
Uninfected immature DCs that had been stained with the green fluorescent dye
CMFDA were added to the infected (unstained) DCs at a ratio of 1:1 (Inf. DCs).
As controls, the supernatant from infected cells (collected directly after washing
off the virus) was added to CMFDA-stained cells (Sup’t) or the green-uninfected
cells were kept in medium (Medium). Maturation (highlighted by arrowheads)
was assessed by CD25 expression 4 days later. The log PE is expressed on the y
axes (CD25 versus the IgG control), and the CMFDA fluorescence intensity is
expressed on the x axes. The results from one of two similar experiments are
provided.
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human and rhesus macaque DCs could be infected with ALVAC
(Table 1 and Fig. 1A and B). This was comparable to the
number of immature DCs that can be infected by fowlpox virus
constructs (8). However, monitoring the infected DCs over the
next few days revealed that considerable cell death was de-
tected in cultures of ALVAC-infected immature human and
macaque DCs. The major mechanism of death in ALVAC-
infected cultures was primarily via apoptosis (Fig. 1C); how-
ever, trypan blue staining also showed that many cells under-
went further secondary necrosis (data not shown). On the
other hand, mature DCs seemed to be more resistant to both
viral infection and ALVAC-induced cell death. This finding
was intriguing, especially since the virus was interacting with a
nonpermissive host (mammalian) cells. Furthermore, similar
cytopathic effects were not reported for fowlpox virus-infected
DCs (8). Interestingly, it has recently become clear that various
DNA and RNA viruses can inhibit apoptosis of infected cells.
Such antiapoptotic genes have been reported for various pox-
viruses such as vaccinia virus, myxoma virus, and tanapoxvirus
(12, 24), but not for ALVAC. Our results suggest that the
cytopathic effects of ALVAC did not require the completion of
the full virus life cycle, since an abortive infection, as seen in
mammalian cells, was effective in damaging infected immature
primate DCs. In contrast, Taylor et al. have reported (57) no
serious side effects after ALVAC infection of various mamma-
lian cell lines in vitro or following infection of laboratory ani-
FIG. 8. Canarypox virus-induced TNF-a production facilitates DC maturation. Immature human DCs were infected or not (Medium) with vCP205 (MOI of 5) and
then incubated in the presence of a blocking anti-human TNF-a Ab or the control isotype immunoglobulin (20 mg/ml). (A) After 18 h the amount of TNF-a secreted
into the supernatants was measured by enzyme-linked immunosorbent assay. (B) DCs were also collected at this time and stained for CD83 expression to monitor DC
maturation. The level of CD83 expression (x axes) is shown for each of the populations. Medium-treated DCs are shown by a light gray line, and vCP205 is represented
with a dark gray line. The CD83-positive subset seen in the immunoglobulin-treated, vCP205-pulsed DCs is indicated with an arrowhead. This subset is lost following
anti-TNF-a treatment. The results represent one of three experiments.
FIG. 7. TNF-a secretion by canarypox virus-infected primate DCs. (A) Immature human DCs were infected with either ALVAC or vCP205 (MOI of 5) or left
uninfected (Medium). Cell supernatants were collected after 24 h and assessed for the presence of TNF-a. The mean TNF-a production from three separate
experiments using different donors is shown. (B) Immature human DCs were infected with ALVAC or vCP205 at the indicated MOIs, and the TNF-a production was
measured 24 h later. (C) Immature rhesus macaque DCs were pulsed with vCP172 (MOI of 10) or not (Medium) and cultured for 1 to 3 days. The TNF-a produced
after 1 and 3 days is shown for animal R887 and after 1 day for animals M284 and F961.
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mals. Notably, when rabbits or squirrel monkeys were injected
with higher doses of ALVAC via the intradermal (i.d.) route,
temporary poxvirus-like skin lesions developed. Furthermore,
virus was recovered from the injection site for up to 4 days
postinjection. This could reflect a similar phenomenon as we
observed in our primary DC system. Considering the high
density of immature DCs in the dermis, DCs may have been
infected with the i.d. injected ALVAC, resulting in DC death
thereby contributing to lesion formation.
When infected “red” DCs were cocultured with uninfected
“green” DCs, large red inclusions were detected in the sorted
red-green double-positive fraction (Fig. 2). Single green cells
contained (at most) low numbers of much smaller red inclu-
sions. This suggested that healthy, uninfected DCs had phago-
cytosed infected, dying DCs. It is important to note that the
double-positive cells showed an intracellular colocalization of
green and red fluorescence, while the rest of the cell surface
seemed rather weakly stained with the green dye. This most
likely indicates that a significant proportion of green-stained
cell membrane of the uninfected DCs was internalized during
the process of phagocytosis. The internalization of the engulf-
ing cells’ membrane with the captured red-labeled infected DC
debris would result in their colocalization within the cell. Be-
cause extensive areas of the residual membrane of the unin-
fected cells would have to be renewed, the green staining of the
rest of the cell appears fainter as a result. The mechanism via
which the infected DC debris was internalized is not known.
However, one receptor, the avb5 integrin is primarily ex-
pressed by immature DCs and has been shown to be involved
in the uptake of apoptotic cells by immature DCs (2).
Further analysis revealed that ALVAC infection of primate
DCs lead to the expression of a more mature DC phenotype,
i.e., increased levels of CD25, CD80, CD83, and CD86 (Fig. 3),
as well as another DC maturation marker, DC-LAMP (11)
(data not shown). While CD80, CD83, and CD86 often ap-
peared to be upregulated on the entire DC population, CD25
expression was restricted to a subset of DCs. Recent studies
indicated that the expression of CD25 correlated with a fully
differentiated mature DC phenotype, as monitored by the sta-
bilization of MHC-peptide complexes on the DC surface (E.
Kampgen, 6th International DC Meeting, May 2000). There-
fore, this suggests that at least a subset of DCs was induced to
completely mature following infection with ALVAC, while the
bulk populations appeared to be somewhat activated. Fewer
infected cells were actually detected in the mature CD25-pos-
itive fraction compared to the CD25-negative and CD25-weak
subset (Fig. 4B). This suggests that infection per se was not
directly causing DC maturation in the cultures. The maturation
effects were solely mediated by the virus and not influenced by
the presence or absence of foreign genes (Fig. 4A). Potential
contaminants within the virus stocks that could induce matu-
ration, such as lipopolysaccharide (5) or mycoplasma (48) were
ruled out using the limulus (BioWhittaker, Walkersville, Md.)
and mycoplasma detection (Gen-Probe Rapid Detection Sys-
tem; Fisher Scientific, Pittsburgh, Pa.) assays (data not shown).
To clarify whether the presence of apoptotic cells contrib-
uted to DC maturation, we treated the infected cultures with
an inhibitor of apoptosis. Caspases have been found to be the
major molecules whose activation leads to apoptotic cell death
(37). Two main pathways have been described. One involves
caspase-8, which is mainly activated after signaling through
receptors belonging to the Fas/TNF-receptor family. In con-
trast, the cytochrome c/Apaf-1 pathway requires caspase-9.
Both pathways ultimately activate caspase-3 as the “effector
caspase.” Therefore, we targeted caspase-3 with the inhibitor
Z-DEVD-FMK, which has been shown to block apoptosis in
vitro (28). In the presence of the caspase 3 inhibitor, there was
a significantly lower number of DCs induced to express CD25
following ALVAC exposure (Fig. 5). Hence, induction of ap-
optosis as a result of ALVAC infection contributed signifi-
cantly to maturation of DCs within these cultures. To date,
only the uptake of necrotic but not primarily apoptotic cells has
been shown to induce DC maturation (21, 50). The contradic-
tions may reflect differences in the way that the cells were
induced to die and, more importantly, that virus-induced cell
death might be very different to freeze-thaw-induced death. Of
note, influenza virus-infected apoptotic monocytes did also fail
to induce DC maturation in those experiments (50). This could
be due to the use of different virus strains in that study as
opposed to our study. Furthermore, as mentioned above, apo-
ptotic ALVAC-infected DCs subsequently underwent second-
ary necrosis, and this also could influence the outcome.
Not all the maturation effect of ALVAC infection was
blocked in the above assays, suggesting either that the inhibi-
tion of apoptosis was incomplete, or that there were additional
apoptosis-independent mechanisms inducing DC maturation.
Subsequent examination revealed that ALVAC-mediated
TNF-a secretion by immature DCs was a significant player in
DC maturation, especially during the early stages (Fig. 7 and
8). Signaling through the TNF receptor family represents one
of the more potent stimuli for DC maturation in vitro and in
vivo resulting in NF-kB activation (5). Interestingly, superna-
tants from necrotic cell lines have recently been reported to
also induce DC maturation; however, these supernatants did
not contain TNF-a (50). Again, this implies that there might be
critical differences in the manner of DC maturation induced by
artificially “killed” cells and virus-mediated events. While the
addition of anti-TNF Abs, which neutralize both secreted and
membrane-bound TNF-a to the ALVAC-infected DCs limited
DC maturation, the effect was not 100% (Fig. 8). Therefore,
our data suggest that both TNF-a secretion and apoptotic cell
death induced by ALVAC infection contribute significantly to
the observed DC maturation. It is possible that other candidate
cytokines such as alpha interferon (IFN-a) may be involved.
IFN-a has been shown to act synergistically with TNF-a on DC
maturation (33, 45). In addition, virus-infected cells, including
immature DCs (40, 56), secrete IFN-a. Therefore, we cannot
exclude that trace amounts of this and other factors may also
be at work here.
How do our findings relate to how ALVAC behaves in vivo?
ALVAC-infected DCs may act directly and present antigens in
vivo. However, it has recently been shown that if a virus does
not target the professional antigen-presenting cells, the activa-
tion of antiviral cytotoxic T cells requires presentation of ex-
ogenous antigen on MHC class I molecules via the alternative
pathway by bone-marrow-derived cells (53). Additional studies
demonstrated that bystander DCs are able to present bacterial
antigens derived from apoptotic Salmonella-infected macro-
phages in the context of both MHC class I and class II mole-
cules (64). Therefore, cross-presentation of viral antigens by
DCs which have matured after engulfing dying infected cells
could contribute to the immunogenicity of ALVAC in mam-
mals. The concomitantly secreted TNF-a could also induce
migration of ALVAC-loaded DCs to the draining lymph nodes
(61) and thereby facilitate immune stimulation. This could be
particularly important when administering ALVAC via the i.d.
route. The skin comprises numerous immature DCs in the
epidermis (Langerhans cells) and dermis (dermal DCs), which
would provide suitable targets for injected ALVAC. Of note,
the i.d. route is the same route used to eradicate smallpox
using a very similar virus and possibly via similar mechanisms,
since vaccinia virus could be detected in Langerhans cells at
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the sites of inoculation (36). In vivo presentation of ALVAC-
borne antigens by DCs is currently under investigation.
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